NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On this news, A ...

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tesla, Inc. ("Tesla" or the "Company") (NASDAQ: TSLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. On news of the NHTSA investigation, Tesla's stock price fell sharply, damaging investors. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of c ...

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Funko, Inc. and its officers or directors [1] Group 1: Company Developments - Funko announced the departure of its CEO, Cynthia Williams, effective July 5, 2025, which led to a significant stock price decline of $0.51 per share, or 10.49%, closing at $4.35 per share on July 7, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - A class action lawsuit has been filed against Broadmark Realty Capital Inc. for alleged securities fraud and unlawful business practices related to a merger [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Broadmark's proxy statement for the merger contained false or misleading statements and failed to disclose critical financial distress among borrowers in Ready Capital's portfolio due to high interest rates [3]. - It is alleged that an oversupply of multifamily properties in Ready Capital's markets limited borrowers' ability to raise rents to cover growing debt costs [3]. - A significant development project acquired during the merger, valued at approximately $500 million, faced catastrophic setbacks, including cost overruns and construction delays [3]. - The lawsuit asserts that Ready Capital's Current Expected Credit Loss reserves and expected credit losses were materially understated, impacting financial projections regarding Distributable Earnings per share, dividends per share, and book value per share [3]. Group 2: Legal Representation - Pomerantz LLP, a firm recognized for its expertise in corporate, securities, and antitrust class litigation, is representing the class in this lawsuit [4].

Group 1 - Centene Corporation is under investigation for potential securities fraud and unlawful business practices involving its officers and directors [1] - On July 1, 2025, Centene withdrew its 2025 GAAP and adjusted diluted earnings per share guidance due to underperformance in market growth across 22 out of 29 states and higher-than-expected health risks affecting revenue calculations [2] - Following the announcement, Centene's stock price dropped by $22.87, or 40.37%, closing at $33.78 per share on July 2, 2025 [3] Group 2 - Pomerantz LLP is a prominent law firm specializing in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4]

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of BellRing Brands, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - During the second quarter 2025 earnings call, BellRing disclosed that certain customers are optimizing their inventories, leading to a slowdown in sales growth to "low-single-digits" for the third quarter [2] - Following the earnings call, BellRing's stock price dropped by $14.88 per share, or 18.97%, closing at $63.55 on May 6, 2025 [2] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3]

Group 1 - The investigation by Pomerantz LLP concerns potential securities fraud or unlawful business practices by Vera Bradley and its officers or directors [1] - Vera Bradley reported disappointing financial results for Q1 of fiscal year 2026, with CEO Jackie Ardrey acknowledging the need for significant improvements to achieve positive growth [3] - Following the announcement of poor financial results, Vera Bradley's stock price dropped by $0.45, or 19.15%, closing at $1.90 per share on June 11, 2025 [4] Group 2 - Vera Bradley announced key leadership changes, including the departure of CEO Jackie Ardrey at the end of July 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving CTO Realty Growth, Inc. following a report by Wolfpack Research that accused the company of misleading investors regarding dividend sustainability and engaging in questionable financial activities [1][3]. Group 1: Investigation and Allegations - Pomerantz LLP is representing investors of CTO Realty Growth, Inc. in an investigation concerning possible securities fraud or other unlawful business practices [1]. - Wolfpack Research published a report on June 25, 2025, alleging that CTO misled investors about its dividend sustainability, leading to a significant drop in stock price [3]. - Following the release of the Wolfpack report, CTO's stock price decreased by $0.98 per share, or 5.42%, closing at $17.10 per share on the same day [3]. Group 2: Company Background - CTO Realty Growth, Inc. is listed on the NYSE under the ticker symbol CTO [1]. - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering substantial damages for victims of securities fraud [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Altimmune, Inc. and its officers or directors following the release of trial results that led to a significant drop in the company's stock price [1][3]. Group 1: Company Overview - Altimmune, Inc. is a publicly traded company on NASDAQ under the ticker symbol ALT [1]. - The company recently announced "topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH)" [3]. Group 2: Trial Results - The trial results were described as "positive," but the key efficacy endpoint showed fibrosis improvement rates of 31.8% and 34.5% for pemvidutide doses of 1.2 mg and 1.8 mg, respectively, compared to 25.9% for placebo, with differences not being statistically significant [3]. - Following the announcement of these results, Altimmune's stock price fell by $4.10 per share, representing a decline of 53.18%, closing at $3.61 per share on June 26, 2025 [3]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors regarding potential securities fraud or other unlawful practices by Altimmune and its management [1]. - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Edgewise Therapeutics and its officers or directors, following a significant stock price drop after clinical trial data was deemed insufficient for accelerated FDA approval [1][3]. Group 1: Company Overview - Edgewise Therapeutics, Inc. is publicly traded on NASDAQ under the ticker EWTX [1]. - The company is focused on developing treatments for Becker and Duchenne muscular dystrophies, with its lead asset being sevasemten [3]. Group 2: Recent Developments - On June 26, 2025, Edgewise reported clinical trial data for sevasemten, which it described as "positive," but the FDA indicated that the data was insufficient for accelerated approval [3]. - Following the announcement, Edgewise's stock price decreased by $1.27, or 8.86%, closing at $14.33 per share [3]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of advocating for victims of securities fraud and corporate misconduct [4].